Clinical trial · Observational
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
NCT04014764CI-TRIAL-00057557(ANSWer)completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, multicenter observational study to collect clinically annotated biospecimens in order to assess the correlation between ex vivo data generated by the Notable assay platform and clinical outcome.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Acute Myelogenous Leukemia | Acute Myeloid Leukemia | ALIAS | 0.90 |
| Chronic Myelogenous Leukemia | Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
| Myeloproliferative Neoplasm | Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| This is a non-interventional study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Single group
- description
- Documented hematologic malignancy in need of starting an active anti-cancer therapy. This is a non-interventional study.
- interventionNames
- Other: This is a non-interventional study
Primary outcomes (1)
- measure
- Clinical response to treatment
- timeFrame
- 3 years
- description
- Collect clinical responses to treatment and outcomes in patients who have provided samples to the biobank
Secondary outcomes (2)
- measure
- Type of clinical treatment responses
- timeFrame
- 3 years
- description
- Correlate ex vivo drug sensitivity data on patient samples with clinical treatment responses.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Provide written informed consent; * Age ≥ 18 years, male or female, of any race; * Documented hematologic malignancy (any of the below) in need of starting an active anti-cancer therapy: * Acute myelogenous leukemia (AML) * Multiple myeloma (MM) * Myelodysplastic syndrome (MDS) * Lymphoma * Acute lymphocytic leukemia (ALL) * Chronic lymphocytic leukemia (CLL) * Chronic myelogenous leukemia (CML) * Neoplasm (MPN) * Other (upon review and approval by medical monitor) Note: \*Supportive care agents including erythropoiesis-stimulating agents (ESAs) such as EPO, Procrit, Aranesp, etc; granulocyte colony stimulating factor (G-CSF); hydroxyurea (Hydrea); and luspatercept (Reblozyl) are not considered anti-cancer therapy for this study * Intent to start anti-cancer therapy within 21 days of biospecimen collection •≥7 days from last anti-cancer therapy; * Any number of prior therapies * Subject cohort is currently open Exclusion Criteria: * Unwilling or unable to give consent * Subject's disease is in remission * Subject cohort is not open at time of consent * Subject is restarting an ongoing treatment regimen after a dose interruption
References
Publications (0)
Data not yet available
No reference posted for this study.